Search Results for

EAY191 – S3 (JIT)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Continue Reading »

---

A022102

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Metastatic  (3)    Neoadjuvant  (2) Brain  (9)    Glioblastoma Multiforme (GBM)  (2)    Other Brain Tumors  (3) Breast  (15)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (1) Cancer Control/Symptom Management  (28) Carcinoid Tumors  (2) Colorectal Cancer  (9)    Metastatic  (2)    Rectal Neoadjuvant  (1) Esophageal Cancer  (2) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (1) Head/Neck Cancer  (8) Leukemia  (2)    Acute Myeloid Leukemia (AML)  (1) Lung Cancer  (23)    Non-Small Cell Lung Cancer  (17)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (3)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (1)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (6)       Extensive Stage SCLC  (3) Lymphoma  (2)    Non-Hodgkin’s Lymphoma  (2) MDS  (1) Melanoma  (3) Merkel Cell Carcinoma  (2) Misc. Gynecology  (3) Multiple Myeloma  (3) Ovarian  (2) Pancreatic  (7)    Metastatic Disease  (2) Prostate  (10) Renal Cell/Kidney Cancer  (4)    Locally Advanced/Metastatic  (2) Sarcoma  (3)